CLINICAL RESEARCH: ACUTE MYOCARDIAL INFARCTION
Plasma Concentrations of Myeloperoxidase Predict Mortality After Myocardial Infarction
Tessa J. Mocatta, MSc*,
Anna P. Pilbrow, PhD ,
Vicky A. Cameron, PhD,
Revathy Senthilmohan, PhD,
Chris M. Frampton, PhD,
A. Mark Richards, MD, PhD and
Christine C. Winterbourn, PhD*,*
* Department of Pathology, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand
Department of Medicine, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand.
Manuscript received September 19, 2006;
revised manuscript received February 9, 2007,
accepted February 20, 2007.
* Reprint requests and correspondence: Dr. Christine C. Winterbourn, Department of Pathology, Christchurch School of Medicine and Health Sciences, P.O. Box 4345, Christchurch 8140, New Zealand. (Email: christine.winterbourn{at}chmeds.ac.nz).
Objectives: This study investigated relationships between plasma myeloperoxidase (MPO), protein oxidation markers, and clinical outcome retrospectively in patients after acute myocardial infarction (MI).
Background: Reactive oxidants are implicated in cardiovascular disease, and elevated plasma MPO is reported to predict adverse outcome in acute coronary syndromes.
Methods: Detailed demographic information, radionuclide ventriculography, neurohormone measurements, and clinical history were obtained for 512 acute MI patients at hospital admission. Plasma levels of MPO and protein carbonyls were measured in patients and 156 heart-healthy control subjects. 3-Chlorotyrosine was measured in selected patients. Patient mortality was followed for 5 years.
Results: Plasma MPO and protein carbonyl concentrations were higher in MI patients 24 h to 96 h after admission than in control subjects (medians: MPO 55 ng/ml vs. 39 ng/ml, and protein carbonyls 48 pmol/mg vs. 17 pmol/mg protein, p < 0.001 for each). Both markers were significantly correlated with each other and with cardiovascular hormone levels. Chlorotyrosine was not elevated in patients with high MPO or carbonyl levels. Above-median levels of MPO but not protein carbonyls were independently predictive of mortality (odds ratio 1.8, 95% confidence interval 1.0 to 3.0, p = 0.034). Patients with above-median MPO levels in combination with above-median plasma amino-terminal pro-brain natriuretic peptide (NT-proBNP) or below-median left ventricular ejection fraction (LVEF) had significantly greater mortality compared with other patients.
Conclusions: Myeloperoxidase and protein carbonyl levels are elevated in plasma after acute MI, apparently via independent mechanisms. High MPO is a risk factor for long-term mortality and adds prognostic value to LVEF and plasma NT-proBNP measurements.
|
Abbreviations and Acronyms
| | ANP = atrial natriuretic peptide | | BNP = brain natriuretic peptide | | IQR = interquartile range | | LVEDV = left ventricular end-diastolic volume | | LVEF = left ventricular ejection fraction | | LVESV = left ventricular end-systolic volume | | MI = myocardial infarction | | MPO = myeloperoxidase | | NT-proANP = amino-terminal pro-atrial natriuretic peptide | | NT-proBNP = amino-terminal pro-brain natriuretic peptide | | PTCA = percutaneous transluminal coronary angioplasty |
|
Related Article
-
Appraisal of Myeloperoxidase for Evaluation of Patients With Suspected Acute Coronary Syndromes
- David A. Morrow
J. Am. Coll. Cardiol. 2007 49: 2001-2002.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
C. B. Wright, Y. Moon, M. C. Paik, T. R. Brown, L. Rabbani, M. Yoshita, C. DeCarli, R. Sacco, and M. S.V. Elkind
Inflammatory Biomarkers of Vascular Risk as Correlates of Leukoariosis
Stroke,
November 1, 2009;
40(11):
3466 - 3471.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Gururajan, P Gurumurthy, P Nayar, S Babu, A Sarasabharati, D Victor, and K M Cherian
Serum myeloperoxidase: a novel biomarker for evaluation of patients with acute coronary syndrome
Heart Asia,
October 15, 2009;
2009(10):
1 - 6.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. D. Wong, H. Gransar, J. Narula, L. Shaw, J. H. Moon, R. Miranda-Peats, A. Rozanski, S. W. Hayes, L. E.J. Thomson, J. D. Friedman, et al.
Myeloperoxidase, Subclinical Atherosclerosis, and Cardiovascular Disease Events
J. Am. Coll. Cardiol. Img.,
September 1, 2009;
2(9):
1093 - 1099.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Schindhelm, L. P. van der Zwan, T. Teerlink, and P. G. Scheffer
Myeloperoxidase: A Useful Biomarker for Cardiovascular Disease Risk Stratification?
Clin. Chem.,
August 1, 2009;
55(8):
1462 - 1470.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Nicholls and S. L. Hazen
Myeloperoxidase, modified lipoproteins, and atherogenesis
J. Lipid Res.,
April 1, 2009;
50(Supplement):
S346 - S351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. B. Shah, W. J. Kop, R. H. Christenson, D. B. Diercks, D. Kuo, S. Henderson, K. Hanson, M. R. Mehra, and C. R. deFilippi
Lack of Diagnostic and Prognostic Utility of Circulating Plasma Myeloperoxidase Concentrations in Patients Presenting with Dyspnea
Clin. Chem.,
January 1, 2009;
55(1):
59 - 67.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. K. Rudolph, V. Rudolph, and S. Baldus
Contribution of Myeloperoxidase to Smoking-dependent Vascular Inflammation
Proceedings of the ATS,
December 1, 2008;
5(8):
820 - 823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Riccioni, V. Capra, N. D'Orazio, T. Bucciarelli, and L. A. Bazzano
Leukotriene modifiers in the treatment of cardiovascular diseases
J. Leukoc. Biol.,
December 1, 2008;
84(6):
1374 - 1378.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. O. Breckwoldt, J. W. Chen, L. Stangenberg, E. Aikawa, E. Rodriguez, S. Qiu, M. A. Moskowitz, and R. Weissleder
Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase
PNAS,
November 25, 2008;
105(47):
18584 - 18589.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Dawson, D. Li, T. Woodward, Z. Barber, L. Wang, and D. J. Paterson
Cardiac cholinergic NO-cGMP signaling following acute myocardial infarction and nNOS gene transfer
Am J Physiol Heart Circ Physiol,
September 1, 2008;
295(3):
H990 - H998.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Shih, S. A. Datwyler, S. C. Hsu, M. S. Matias, D. P. Pacenti, C. Lueders, C. Mueller, O. Danne, and M. Mockel
Effect of Collection Tube Type and Preanalytical Handling on Myeloperoxidase Concentrations
Clin. Chem.,
June 1, 2008;
54(6):
1076 - 1079.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Morrow, M. S. Sabatine, M.-L. Brennan, J. A. de Lemos, S. A. Murphy, C. T. Ruff, N. Rifai, C. P. Cannon, and S. L. Hazen
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18
Eur. Heart J.,
May 1, 2008;
29(9):
1096 - 1102.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nahrendorf, D. Sosnovik, J. W. Chen, P. Panizzi, J.-L. Figueiredo, E. Aikawa, P. Libby, F. K. Swirski, and R. Weissleder
Activatable Magnetic Resonance Imaging Agent Reports Myeloperoxidase Activity in Healing Infarcts and Noninvasively Detects the Antiinflammatory Effects of Atorvastatin on Ischemia-Reperfusion Injury
Circulation,
March 4, 2008;
117(9):
1153 - 1160.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the year in JACC 2007.
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
490 - 512.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. L. Gornik
Peripheral arterial disease enters the biomarker era. Does risk stratification tell us something that we don't already know?
Eur. Heart J.,
January 2, 2008;
29(2):
150 - 152.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Morrow
Appraisal of Myeloperoxidase for Evaluation of Patients With Suspected Acute Coronary Syndromes
J. Am. Coll. Cardiol.,
May 22, 2007;
49(20):
2001 - 2002.
[Full Text]
[PDF]
|
|
|
|
